ten23 health Acquires swissfillon to Enhance its Integrated Offering

Global contract development and manufacturing organization (CDMO), ten23 health, has acquired filling technology and drug product manufacturing expert, swissfillon, it was announced in an Oct. 25, 2021 press release.

The acquisition will enhance ten23 health’s integrated offering of sterile drug product development and manufacturing of biologics, challenging molecules, and dosage forms. The swissfillon brand will continue to be used for operations.

“We look forward to joining ten23 health’s world-class team. There is a great strategic fit between our profound expertise in sterile drug product manufacturing for complex pharmaceuticals and ten23 health’s focus on the development and manufacturing of injectable treatments,” said Daniel Kehl, current CEO of swissfillon, in the press release. “By pooling our profound expertise, we will be able to further expand our market position for injectable treatments. The swissfillon team looks forward to continue advancing under the ten23 health umbrella and providing our combined group of customers with excellent support and customizable solutions.”

“Sterile fill/finish services are expected to experience significant growth over the coming years. The rising demand is driven by expanded drug development pipelines, incorporating more complex, large-molecule products and therapies that require specific expertise for both development and sterile production,” added Hanns-Christian Mahler, CEO of ten23 health, in the press release. “This is precisely why we expect ten23 health´s services, now including swissfillon, to be in great demand. At ten23 health, we are very pleased that we can now offer this sought-after know-how to biotech startups and pharmaceutical companies from one single source.”

Source: ten23 health